New pages

16 September 2026

• 19:0919:09, 16 September 2026 The Chronic Total Occlusion (hist | edit) [50,741 bytes] Anum Ijaz (talk | contribs) (Created page with "__NOTOC__ {{Percutaneous Coronary Intervention}} {{CMG}}; {{AIJ}} ==Overview== A coronary chronic total occlusion is a completely occluded epicardial coronary artery with no antegrade flow through the occluded segment and an estimated occlusion duration of at least three months. The lesion is found in roughly one in five patients with significant coronary artery disease at diagnostic angiography, yet only a minority of these patients are offered percutaneous...") Tag: Visual edit
• 14:0514:05, 16 September 2026 Management of Coronary Bridge Lesions and Kinks (hist | edit) [29,958 bytes] Anum Ijaz (talk | contribs) (Created page with "__NOTOC__ {{Percutaneous Coronary Intervention}} {{CMG}}; {{AIJ}} ==Overview== A myocardial bridge is a congenital coronary artery anomaly in which a segment of an epicardial coronary artery runs within the myocardium rather than over it. The overlying muscle is the bridge and the intramyocardial segment is the tunneled artery. Most bridges involve the mid or distal left anterior descending artery and most are incidental. A minority produce angina, [...") Tag: Visual edit: Switched originally created as "Management of Coronary Bridge Lesions and Kinks and"

9 September 2026

• 14:4514:45, 9 September 2026 Thyroid storm Treatment (hist | edit) [3,281 bytes] Nehal Eid (talk | contribs) (Created page with " === Pharmacotherapy === The main aims of medical therapy are as follows- # Reduce effects of thyroid hormone on peripheral tissues. # Decrease further synthesis of thyroid hormone # Decrease release of hormone # Prevent further TH secretion and peripheral conversion of T4 to T3. The medications used to accomplish the above aims are described as follows (in order of the aims)- ; 1) Beta-blockers : Beta blockers block peripheral conversion of T4 to T3. Exercise cautio...") Tag: Visual edit
• 14:3914:39, 9 September 2026 Thyroid storm Diagnosis (hist | edit) [4,340 bytes] Nehal Eid (talk | contribs) (Created page with "==History== The patient may be a known case of hyperthyroidism or may present initially with severe symptoms of thyroid storm. ==Symptoms== Hyperpyrexia ie. temperature > 104'F, tachycardia > 140/min or Atrial fibrillation and delirium or agitation are typical features of thyroid storm. Other features include - General- profuse sweating, poor feeding, weight loss, respiratory distress, fatigue. Cardiovascular- pulmonary edema, hypotension, arrhythmia and death from car...")
• 14:3414:34, 9 September 2026 Thyroid storm Epidemiology and Demographics (hist | edit) [430 bytes] Nehal Eid (talk | contribs) (Created page with "=== Age === Children aged 10-15 years account for greater than 2/3rd cases of thyrotoxicosis. Hence, thyroid storm is more common in adolescents though it can occur in any age group. === Gender === Hyperthyroidism is 3-5 times more common in females than males. Incidence of thyroid storm is presumed to be higher in females but no clear data is available. === Race === === Developed Countries === === Developing Countries ===") Tag: Visual edit
• 14:2014:20, 9 September 2026 Thyroid storm Causes (hist | edit) [3,581 bytes] Nehal Eid (talk | contribs) (Created page with "===Common Causes=== *Any surgery *Direct trauma to the gland *Recent infection *Withdrawal or non compliance with antithyroid medication *Medical stressors like myocardial infarction *Acute iodine load *Parturition ===Causes by Organ System=== {|style="width:80%; height:100px" border="1" |style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" | '''Cardiovascular''' |style="height:100px"; style="width:75%" border="1...")
• 14:1614:16, 9 September 2026 Thyroid storm pathophysiology (hist | edit) [230 bytes] Nehal Eid (talk | contribs) (Created page with "==Genetics== ==Associated Conditions== ==Gross Pathology== ==Microscopic Pathology==")

3 September 2026

• 22:0822:08, 3 September 2026 KYGEVVI- doxecitine and doxribtimine powder, for solution (hist | edit) [42,623 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=combination of pyrimidine nucleosides |indicationType=treatment |indication=thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. |adverseReactions=diarrhea, abdominal pain (including abdominal pain upper), vomiting, alanine aminotransferase increased (ALT), and aspartate aminotransferase increased (AST). |blackBoxWarningTitle='''<span st...")
• 21:4821:48, 3 September 2026 NUZOLVENCE- zoliflodacin for suspension (hist | edit) [40,514 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=spiropyrimidinetrione bacterial type II topoisomerase inhibitor |indicationType=treatment |indication=uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg. |adverseReactions=neutropenia, headache, leukopenia, dizziness, nausea, and diarrhea. |blackBoxWarningTitle='''<span style="color:#FF0000;">T...")

2 September 2026

• 20:5320:53, 2 September 2026 LEROCHOL- lerodalcibep-liga injection, solution (hist | edit) [27,783 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=lerodalcibep-liga |aOrAn=a |drugClass=proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor |indicationType=treatment |indication=low-density lipoprotein cholesterol (LDL-C)(reduction) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and exercise. |adverseReactions=injection site reactions, nasopharyngitis, diarrhea, nausea and...")
• 20:3820:38, 2 September 2026 VOYXACT- sibeprenlimab injection (hist | edit) [22,539 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=sibeprenlimab-szsi |aOrAn=an |drugClass=A Proliferation Inducing Ligand (APRIL) blocker |indicationType=treatment |indication=( reduction of) proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression |adverseReactions=infections and injection site reactions. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color...")
• 20:1220:12, 2 September 2026 HYRNUO- sevabertinib tablet, film coated (hist | edit) [50,422 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adult patients whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. |adverseReactions=diarrhea, rash, paronychia, stomatitis, and nausea. |bl...")

27 August 2026

• 19:4019:40, 27 August 2026 REDEMPLO- plozasiran injection, solution (hist | edit) [23,375 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=an |drugClass=apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA) |indicationType=treatment |indication=for hypertriglyceridemia in adults with familial chylomicronemia syndrome (FCS), as an adjunct to diet. |adverseReactions=hyperglycemia, headache, nausea, and injection site reaction. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span st...")
• 19:2719:27, 27 August 2026 KOMZIFTI- ziftomenib capsule (hist | edit) [45,411 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=menin inhibitor |indicationType=treatment |indication=relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult patients who have no satisfactory alternative treatment options. |hasBlackBoxWarning=Yes |adverseReactions=aspartate aminotransferase increase, infection without an identified pathogen, potassium decreased, albumin decreased, alanine...")
• 18:4118:41, 27 August 2026 LYNKUET- elinzanetant capsule (hist | edit) [40,988 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=neurokinin receptor antagonist |indicationType=treatment |indication=moderate to severe vasomotor symptoms (VMS) due to menopause. |adverseReactions=headache, fatigue, gastroesophageal reflux disease, dizziness, nausea, and somnolence. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |fdaLIA...")

26 August 2026

• 20:3820:38, 26 August 2026 JASCAYD- nerandomilast tablet, film coated (hist | edit) [45,041 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=phosphodiesterase 4 (PDE4) inhibitor |indicationType=treatment |indication=idiopathic pulmonary fibrosis (IPF) in adult patients, and progressive pulmonary fibrosis (PPF) in adult patients. |adverseReactions=diarrhea, COVID-19, upper respiratory tract infection, depression, weight decreased, decreased appetite, nausea, fatigue, headache, vomiting, back pain, and dizziness. |blackBoxWarningTitl...")
• 20:0120:01, 26 August 2026 RHAPSIDO- remibrutinib tablet (hist | edit) [30,531 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. |adverseReactions=nasopharyngitis, bleeding, headache, nausea and abdominal pain. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:<...")
• 19:5119:51, 26 August 2026 INLURIYO- imlunestrant tablet, film coated (hist | edit) [33,065 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=an |drugClass=estrogen receptor antagonist |indicationType=treatment |indication=adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. |adverseReactions=hemoglobin decreased, musculoskeletal pain, calcium...")

24 August 2026

• 18:3518:35, 24 August 2026 FORZINITY- elamipretide hydrochloride injection (hist | edit) [25,894 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=mitochondrial cardiolipin binder. |indicationType=treatment |indication=Barth syndrome in adult and pediatric patients weighing at least 30 kg, to improve muscle strength. |adverseReactions=injection site reactions. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |fdaLIADAdult====Barth Syndrome...")
• 18:2018:20, 24 August 2026 WAYRILZ- rilzabrutinib tablet, film coated (hist | edit) [35,588 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=Bruton's tyrosine kinase (BTK) inhibitor |indicationType=treatment |indication=adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. |adverseReactions=diarrhea, nausea, headache, abdominal pain, and COVID-19. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<...")